AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company that came to market through a de-SPAC transaction with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra Sponsor, LLC that completed its IPO in 2021. The company is focused on developing proprietary botulinum toxin formulations as therapeutic candidates across several neurological and movement-disorder indications. The 10-Q filing dated August 12, 2022, reflects the company's reporting obligations during the post-combination period as it advanced its clinical pipeline in the biopharmaceutical sector. Sign up for SpacDesk to access the full filing history, deal terms, and sponsor profile for AEON Biopharma and hundreds of other SPAC transactions.